The National Institute for Health and Care Excellence (NICE) has announced that EYLEA (aflibercept solution for intravitreal injection, known in the scientific literature as VEGF Trap-Eye).
Should be recommended as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). When guidance is finalised NHS bodies will have 90 days to ensure EYLEA is made available to all eligible patients.
Improving patient care through innovation in visualization
Focused on transforming the delivery of care, Barco connects healthcare professionals from the radiology department, through the pathology lab and specialist consultations into the surgical suite.
With almost 40 years of experience in medical imaging, we offer a network of...
Coventry Building Society Arena, Coventry
24th – 25th June 2026
INNSiDE by Meliá Manchester
20th June 2026
Division of Anatomy, University of Leeds
29th- 30th June 2026
Wrightington Conference Centre
Tuesday 7th – Wednesday 8th July 2026
B. Braun Business Centre, Sheffield
Friday 10th July 2026
BAWA Leisure
18th July 2026
